UROonco24: Scientific programme preview from Prof. Rouprêt

The scientific programme this year is extensive, with 11 plenary sessions filled with lectures, rapid-fire debates, and clinical and case discussions that provide essential updates in prostate, bladder, kidney, testis, and penile cancer.

Prof. Rouprêt: “These highlights underscore UROonco24’s commitment to providing cutting-edge research, practical skills training, and interactive learning opportunities.”

Rapid fire debates – common problems in PCa

Prof. Rouprêt: “One of the highly anticipated sessions is ‘Prostate cancer I: Rapid fire debates – common problems in prostate cancer’. The four cases that will be debated include: How best to follow patients with low-risk prostate cancer on active surveillance; Can PSMA PET/CT spare extended pelvic lymph node dissection in high-risk prostate cancer?; Oligometastatic recurrence after primary local treatment detection on PSMA PET/CT: How to treat; and PARPi + ARPI for all patients with metastatic castration resistant prostate cancer?’. These discussions will provide insights into new trials, making it a must-attend for anyone involved in prostate cancer management”.

Update sessions for PCa, BCa, and RCC

“The meeting will feature interactive roundtable discussions on prostate, bladder, and kidney cancers. These sessions are designed to deliver comprehensive updates and facilitate active participation from delegates, enabling a deep dive into the latest advancements and challenges in each cancer type.”

For prostate cancer, topics include: ‘Enhancing detection of lymph node-positive prostate cancer through molecular imaging, is it worth the effort?’, including results on new trials such as PRIMORDIUM; and ‘De novo metastatic disease in 2024: a matter of staging and sequencing’.

For bladder cancer, the cases will cover ‘High grade recurrence after BCG treatment: importance of BCG exposure and available options’; and ‘Good response after neoadjuvant chemotherapy for clinical node disease, when should we go for surgery?’.

For renal cancer, topics include: ‘Decision-making for a large localised (ct1Bb) renal mass: Any role of virtual biopsy?’; and ‘Adjuvant pembrolizumab for high-risk ccRCC: How to optimise patient selection and treatment at recurrence.’

Clinical trial corner

UROonco24 is a great avenue for Europe-based urologists to get the latest research and updates from international urological gatherings such as ESMO, ASCO GU, AUA and ASCO. There will be presentations and discussion on the latest onco-urology trials, such as PRIME, EMBARK, RADICALS-RT, PRISMA, NURE-COMBO and KEYNOTE-564.

—

What else is on the agenda?

• The ESU-ESOU-ESUI Education session features molecular imaging, as well as a rapid-fire debate on PSMA guided treatment. Prof. Karolien Goffin (BE) and Prof. Declan Murphy (AU) will debate theranostics in mHSPC with a nuclear medicine vs clinical point of view, respectively.
• Find out about the different geographical perspectives in the Real-world Urology session, which will feature prostate cancer screening, high-risk prostate cancer management, and oligometastatic prostate cancer management.
• During the European Urology Oncology session, the best of onco-urology journals will be shared for prostate cancer, urothelial cancer, rare tumours, and renal cancer. There will also be an award presentation for the best paper published in the European Urology Oncology over the year, with the winning author sharing their article highlights.
• ESU/ESUI Hands-on training course for ’Prostate MRI reading’ for urologists.

See the full scientific programme here, and register before 6 June, 2024 (23:59 CEST) to benefit from savings with the late registration fee.